A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Clinical trial NCT03551782 · COMPLETED
Trial details
- NCT number
- NCT03551782
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-28
- Primary completion
- 2021-11-11
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.